NICE Rejects Novartis’ Kymriah

NICE decided not to recommend Novartis’ Kymriah (tisagenlecleucel-T) to the NHS as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.

The UK institute’s technology appraisal committee ruled that the CAR-T drug was not cost-effective, noting it requires trained specialists for “extensive monitoring” and has multiple side effects.

The panel will consider comments on the draft recommendation and any new evidence at its Oct. 23 meeting.